Pascal Biosciences Inc (NEVI) AI Stock Analysis

• Market Cap: C$1.78M
• Dividend Yield: N/A
• Average Volume (3M): 55.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.56
• Revenue Growth: -6.85%
• EPS Growth: 22.09%
• Country: CA
• Employees: 2
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Beverages - Non-Alcoholic
• EPS (TTM): >-0.01
• Shares Outstanding: 39,662,727
• 10 Day Avg. Volume: 84,932
• 30 Day Avg. Volume: 55,489
• PEG Ratio: 0.25
• Price to Book (P/B): 3.28
• Price to Sales (P/S): 2.60
• P/FCF Ratio: -30.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.05 ▼(-30.00% Downside)

The score is held back primarily by ongoing unprofitability and negative operating/free cash flow despite improving revenue growth and positive EBITDA. Technicals are mixed with the price below key longer-term moving averages and negative MACD, while valuation is difficult to support due to a negative P/E and no dividend yield.

Positive Factors

Revenue Growth

The moderate improvement in revenue suggests Pascal Biosciences is expanding its market presence and product adoption, which is crucial for long-term growth in the biopharmaceutical sector.

Cash Flow Improvement

Positive free cash flow indicates better cash management and operational efficiency, providing financial flexibility for future investments and growth.

Gross Profit Margin

A healthy gross profit margin demonstrates strong pricing power and cost management, essential for sustaining profitability as the company scales.

Negative Factors

Profitability Challenges

Ongoing profitability challenges highlight the need for cost control and revenue growth to achieve sustainable financial health, impacting long-term viability.

Historical Negative Equity

Historical negative equity suggests past financial struggles, potentially limiting access to capital and affecting investor confidence in the company's stability.

Reliance on Financing

Dependence on external financing could strain financial resources and increase risk, especially if market conditions tighten or interest rates rise.

Pascal Biosciences Inc Business Overview & Revenue Model

Company Description

Pascal Biosciences Inc. (NEVI) is a biotechnology company focused on developing innovative therapies for the treatment of cancer and other serious diseases. The company operates primarily in the biopharmaceutical sector, leveraging advanced research and technology to create novel drug candidates. Pascal Biosciences is engaged in the discovery and development of therapies that aim to enhance the immune response to tumors, with a pipeline that includes both biologics and small molecules designed to address unmet medical needs in oncology.

How the Company Makes Money

Pascal Biosciences generates revenue primarily through the development and commercialization of its therapeutic products. The company may earn money through various channels, including licensing agreements with larger pharmaceutical firms, grants, and potential partnerships that provide funding for research and development activities. Additionally, if any of its drug candidates advance to late-stage clinical trials or receive regulatory approval, the company could profit from product sales, milestone payments, and royalties from licensing deals. Strategic collaborations with academic institutions and other biotech companies also contribute to its financial resources, enabling Pascal Biosciences to expand its research capabilities and accelerate the development of its pipeline.

Pascal Biosciences Inc Financial Statement Overview

Summary

Financials are improving but still weak overall: strong TTM revenue growth (26.9%) and solid gross margin (62.3%) with EBITDA turning positive (4.7% margin). However, the company remains unprofitable (TTM net margin -17.0%) and continues to burn cash (negative operating and free cash flow), which limits the score.

Income Statement

Top-line momentum is improving: revenue grew 26.9% in TTM (Trailing-Twelve-Months) and remains well above the 2023 level. Profitability is mixed—gross margin is solid (62.3% in TTM), and EBITDA has turned positive (4.7% margin), but the business is still losing money with negative operating profit and a net loss (net margin -17.0% in TTM). Overall, the trajectory is better than prior years, but earnings quality is not yet strong enough to score higher.

Balance Sheet

Leverage looks manageable with debt-to-equity at 0.21 in TTM (Trailing-Twelve-Months), improving from ~0.50 in 2023, suggesting reduced balance-sheet risk from borrowing. Equity is positive and sizable relative to assets (equity $1.18M vs. assets $1.84M in TTM), a meaningful improvement versus earlier periods that showed negative equity. The key weakness is ongoing losses, reflected in negative returns on equity, which could pressure the balance sheet if not corrected.

Cash Flow

Cash generation remains a clear weak spot: operating cash flow and free cash flow are negative in TTM (Trailing-Twelve-Months) (both about -$86.8K), indicating the business is not yet self-funding. While the cash burn has improved substantially versus 2023 (operating cash flow was -$385K), free cash flow growth is sharply negative in TTM, signaling volatility rather than a steady improving trend. Until operating cash flow turns sustainably positive, cash flow quality and funding risk remain concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.57M	1.55M	671.54K	0.00	0.00	0.00
Gross Profit	979.59K	1.08M	392.94K	-8.29K	-16.32K	-12.48K
EBITDA	73.23K	-48.07K	-271.56K	-468.09K	-1.07M	-1.22M
Net Income	-267.33K	-362.48K	-399.77K	-480.28K	-1.09M	-1.24M
Balance Sheet
Total Assets	1.84M	2.04M	2.50M	18.82K	155.19K	120.71K
Cash, Cash Equivalents and Short-Term Investments	34.56K	129.54K	418.52K	8.37K	0.00	0.00
Total Debt	249.37K	528.30K	683.27K	224.62K	7.76K	16.91K
Total Liabilities	665.43K	813.50K	1.12M	962.93K	646.48K	473.05K
Stockholders Equity	1.18M	1.23M	1.38M	-944.11K	-491.30K	-352.34K
Cash Flow
Free Cash Flow	-86.76K	-132.06K	-390.49K	-147.68K	-614.93K	-862.83K
Operating Cash Flow	-86.76K	-120.50K	-385.35K	-147.68K	-614.93K	-862.83K
Investing Cash Flow	70.33K	-11.56K	-947.71K	8.98K	0.00	0.00
Financing Cash Flow	-70.73K	-167.65K	1.76M	154.84K	624.08K	471.07K

Pascal Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NEVI, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and above the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.25 is Neutral, neither overbought nor oversold. The STOCH value of -33.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NEVI.

Pascal Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
MEAT	47 Neutral	C$1.48M	-2.30	―	―	-3.76%	86.34%
NEVI	44 Neutral	C$1.78M	-5.97	-21.78%	―	-6.85%	22.09%
LFST	41 Neutral	C$1.33M	-0.47	-129.49%	―	-98.28%	76.18%

Pascal Biosciences Inc Corporate Events

Nevis Brands Expands Market Presence and Strengthens Financial Position

Nevis Brands Inc. has announced significant corporate updates, including the relaunch of its Major beverages in Arizona and an expansion of Happy Apple THC beverages into Ohio through a prominent distributor in Columbus. The company has also made progress in reducing its financial obligations, completing a substantial payment towards its note payable to SoRSE Technology. These developments strengthen Nevis Brands’ market presence and position the company for further growth in 2026, despite regulatory challenges anticipated for hemp-derived THC products.

The most recent analyst rating on (TSE:NEVI) stock is a Hold with a C$0.05 price target. To see the full list of analyst forecasts on Pascal Biosciences Inc stock, see the TSE:NEVI Stock Forecast page.

Nevis Brands Expands Major™ Cannabis Beverage Line in U.S. Markets

Nevis Brands Inc. has announced the expansion of its Major™ cannabis beverage line, launching 100mg THC shots in New Mexico and re-entering the Arizona market. This strategic move enhances Nevis Brands’ presence in key U.S. markets, leveraging its manufacturing partnerships and regulatory expertise to meet growing consumer demand for innovative cannabis products. The expansion is expected to strengthen the company’s market position and diversify its product portfolio, offering consumers a potent and convenient option in the recreational cannabis landscape.

Nevis Brands Reports 16% Revenue Growth in Q3 2025 Amid Market Expansion

Nevis Brands Inc. reported a 16% revenue growth in Q3 2025, driven by expanding sales in licensed markets and the promising performance of its hemp-derived THC product line. Despite a slight decrease in gross profit margins due to increased testing costs and initial production expenses, the company remains optimistic about future margin improvements as production scales. Nevis is experiencing geographic expansion and stable performance in core markets, with new market entries in New Jersey and Missouri. The company is poised for wider national distribution through additional distributor agreements, focusing on scaling hemp-derived offerings while maintaining disciplined cost management.